Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Madalena association in type 2 diabetes mellitus
NCT04670666Phase 3Recruiting
- Sponsor
- EMS
- Start
- Nov 2024
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of empagliflozin + linagliptin + metformin in type 2 diabetes mellitus (T2DM), sponsored by EMS. Started Nov 2024; status: recruiting.
02
Drugs
empagliflozin + linagliptin + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04670666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04670666.